Growth Hormone Pulsatility

Growth hormone (GH) is not released at a steady rate. The anterior pituitary secretes GH in sharp bursts separated by troughs of very low or undetectable circulating levels. This pulsatile pattern is not incidental — it is the primary determinant of GH's biological effects. The same total daily GH output produces fundamentally different outcomes depending on whether it arrives in discrete pulses or as a continuous stream.

The GHRH-somatostatin oscillator

GH pulsatility is generated by alternating activity of two hypothalamic peptides. GHRH, from the arcuate nucleus, stimulates GH synthesis and secretion. Somatostatin, from the periventricular nucleus, inhibits GH release without affecting synthesis. These neuronal populations fire reciprocally — when GHRH tone is high, somatostatin tone is low.

A GH pulse occurs when somatostatin withdraws and GHRH is simultaneously released. Somatotrophs primed during the somatostatin-dominant phase respond with a burst of secretion. The pulse terminates as somatostatin returns.

This oscillation produces 6 to 12 detectable pulses per 24 hours. The largest occur during slow-wave sleep, typically within the first hour of sleep onset. A third signal — ghrelin, acting through GHS-R1a — amplifies pulse amplitude by synergizing with GHRH at the somatotroph. Ghrelin does not initiate pulses independently but increases their magnitude.

Sexual dimorphism in GH patterns

Male and female GH secretion patterns differ markedly, driving sex-specific hepatic gene expression.

Male pattern: high-amplitude pulses separated by very low interpulse troughs (often below detection). The GH-free intervals allow STAT5b signaling to fully deactivate and reset in hepatocytes, enabling each pulse to trigger a fresh signaling cascade.

Female pattern: more frequent, lower-amplitude pulses with higher basal interpulse levels. Troughs never reach the near-zero values seen in males, activating a distinct hepatic transcriptional program.

In rodent models, feminizing the male GH pattern by continuous infusion switches the hepatic transcriptional profile to a female pattern. The affected genes include cytochrome P450 enzymes responsible for sex-specific drug metabolism, lipoproteins, and acute-phase proteins.

How GHS peptides interact with pulsatility

Short-acting GHS peptides (GHRP-2, GHRP-6, ipamorelin) create an acute GH pulse within 15 to 30 minutes that resolves over 1 to 2 hours. When co-administered with a GHRH analog, the result is a synergistically amplified physiological pulse. Dosed once or twice daily, these peptides augment the pulsatile pattern without eliminating interpulse troughs.

Long-acting GHS agonists (MK-677) increase both pulse amplitude and basal GH levels with daily dosing. The pulsatile pattern is preserved but interpulse troughs are elevated. Whether this partially continuous elevation produces meaningfully different signaling remains under investigation.

Continuous GHS infusion abolishes normal pulsatility. Constant GHS-R1a stimulation leads to rapid receptor desensitization — GH output falls toward baseline within days.

Why pulsatility matters for downstream signaling

The most compelling evidence that pulsatility is functionally required comes from the JAK2-STAT5b pathway. When GH binds its receptor, JAK2 phosphorylates STAT5b, which dimerizes, translocates to the nucleus, and activates target genes. Critically, negative feedback regulators — SOCS proteins and SHP phosphatases — deactivate this signaling within 1 to 2 hours. The machinery must reset during a GH-free interval before responding fully to the next pulse.

Continuous GH exposure keeps SOCS proteins chronically elevated, creating a refractory state where STAT5b is poorly activated despite continuous receptor occupancy. Pulsatile exposure allows SOCS to fall between pulses, enabling full signaling with each burst.

This has direct implications: protocols maintaining elevated GH throughout the day may produce less effective STAT5b signaling per unit of GH than protocols delivering the same total GH in fewer, larger, well-separated pulses.

Practical considerations

The biology of pulsatility suggests several principles. Fewer, larger pulses are generally more effective than frequent small elevations for STAT5b-dependent outcomes. Preserving low interpulse troughs maintains the full dynamic range of signaling. GHRH-GHS co-administration amplifies pulses synergistically because the peptides act through complementary receptors. Bedtime dosing aligns pharmacological pulses with the natural sleep-associated GH surge, leveraging the somatostatin withdrawal that occurs at sleep onset.